AstraZeneca Gets CDSCO Panel Nod for Enhertu 100mg for additional indication of breast cancer Dr. Divya Colin25 Dec 2023 6:00 PM ISTNew Delhi: Noting an unmet medical need in the country, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
AstraZeneca-Daiichi Sankyo Enhertu approved in EU for lung cancer Ruchika Sharma24 Oct 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the...
AstraZeneca-Daiichi Sankyo Enhertu gets two breakthrough therapy designations in US for multiple HER2 expressing cancers Ruchika Sharma3 Sept 2023 4:00 PM ISTTokyo: Daiichi Sankyo has announced that ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations...
Daiichi Sankyo Enhertu approved in Japan as first HER2 directed therapy for patients with HER2 mutant metastatic lung cancer Ruchika Sharma25 Aug 2023 10:00 AM ISTTokyo: Daiichi Sankyo has announced that ENHERTU (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with...
AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer Ruchika Sharma16 July 2023 1:00 PM ISTEnhertu is a HER2-directed ADC.
AstraZeneca Enhertu shows clinically meaningful, durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial Ruchika Sharma8 March 2023 1:00 PM ISTHER2 is a tyrosine kinase receptor protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell growth.
AstraZeneca-Daiichi Sankyo Enhertu approved in China for breast cancer Ruchika Sharma25 Feb 2023 1:30 PM ISTUK: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult...
Experts say patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement Ruchika Sharma10 Dec 2022 1:30 PM ISTUK: The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to...
Daiichi Sankyo ENHERTU gets Japanese nod for patients with previously treated HER2 Positive Metastatic Breast Cancer Ruchika Sharma25 Nov 2022 1:30 PM ISTENHERTU (trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC.
AstraZeneca- Daiichi Sankyo Enhertu recommended for nod in EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer Ruchika Sharma15 Nov 2022 12:15 PM ISTEnhertu is a HER2-directed ADC.
Thermo Fisher Scientific secures USFDA nod for Oncomine Dx Target Test for lung cancers with HER2 mutations Ruchika Sharma15 Aug 2022 12:00 PM ISTThe Oncomine Dx Target Test is designed to simultaneously evaluate 23 genes associated with NSCLC.
AstraZeneca, Daiichi Sankyo get USFDA accelerated nod for Enhertu for HER2 Mutant Non-small Cell Lung Cancer Ruchika Sharma14 Aug 2022 3:30 PM ISTEnhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi...
